{"id":"18940431725-51","name":"F. Hoffmann-La Roche Ltd","registrationDate":"2009-05-20T10:57:35.956+02:00","category":2,"subCategory":3,"legal":"Corporation","web":"http://www.roche.com","country":"Switzerland","headAddress":"Grenzacherstrasse, 124","headCity":"Basel","headPostCode":"4070","headPhone":"(41)6 16 88 11 11","boss":"Severin Schwan","bossTitle":"Mr","bossPosition":"CEO","membersCount":9,"membersFTE":"3.5","membership":"Roche is a member of EFPIA, MedTech Europe and national pharmaceutical and diagnostics associations, EBE, EAPM, Kangaroo Group, AMISA2.","memberOrga":"","goal":"Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.&#xd;<br />&#xd;<br />Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.&#xd;<br />&#xd;<br />Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).&#xd;<br />&#xd;<br />The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide.","acronym":"Roche","interests":"Budget, Business and Industry, Competition, Consumers, Digital economy and society, Economy, finance and the euro, Environment, External Relations, Institutional affairs, International co-operation and development, Justice and Fundamental Rights, Public Health, Research and innovation, Single market, Trade","euInitiatives":"Main EU initiatives, policies and legislative files followed by the organisation:&#xd;<br />– Interactions (direct contacts) with EU Institutions relating to legislation and implementation of EU regulation at national level: e.g. Access to Medicines, Incentives, Health Technology Assessment, IVD / Medical Devices Regulations, Data Protection Regulation/Digitalisation, Horizon Europe, Pharmaceuticals in the Environment, Falsified Medicines Directive&#xd;<br />– Our expertise and knowledge enables us to contribute convincing arguments on policy topics that are of high priority to us, such as:&#xd;<br />-How to provide patients with timely and safe access to medicines and diagnostics.&#xd;<br />-How to create a culture which fosters innovation, e.g. by granting intellectual property (IP) protection.&#xd;<br />-How to get a fair value for innovative products, devices and services.&#xd;<br />-How to use innovative approaches to personalised healthcare. This includes making use of big data while protecting data privacy&#xd;<br />– Provide input to EU Institutions open consultations, including participation in events sponsored by EU Institutions&#xd;<br />– Improve patient safety and strengthen disease prevention in Europe&#xd;<br />– Provide coverage and reimbursement that reward innovation&#xd;<br />– Increase Europe's competitiveness as a location for Research and Development investment&#xd;<br />– Pharmaceuticals, Diagnostics, Diabetes Care, Intellectual Property, Trade","lastUp":"2019-04-11T09:54:00.117+02:00","customers":"","costAbsolu":"","costRange":"1000000-1249999","turnoverAbsolu":0,"turnoverRange":""}